Serum S100 calcium binding protein A4 (S100A4, metatasin) as a diagnostic and prognostic biomarker in epithelial ovarian cancer
Authors:
- 9 February 2018
- journal article
- research article
- Published by Frontiers Media SA in British Journal of Biomedical Science
- Vol. 75 (2) , 88-91
Abstract
(2018). Serum S100 calcium binding protein A4 (S100A4, metatasin) as a diagnostic and prognostic biomarker in epithelial ovarian cancer. British Journal of Biomedical Science: Vol. 75, No. 2, pp. 88-91.Keywords
This publication has 11 references indexed in Scilit:
- Evaluation and screening of mRNA S100A genes as serological biomarkers in different stages of bladder cancer in EgyptTumor Biology, 2015
- S100 proteins in cancerNature Reviews Cancer, 2015
- Epithelial ovarian cancer experimental modelsOncogene, 2013
- S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidenceCancer and Metastasis Reviews, 2011
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialThe Lancet, 2010
- S100A4 and MetastasisThe American Journal of Pathology, 2010
- Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancerGynecologic Oncology, 2009
- Different Expression and Clinical Role of S100A4 in Serous Ovarian Carcinoma at Different Anatomic SitesTumor Biology, 2009
- Serum metastasin mRNA is an important survival predictor in breast cancerBritish Journal of Biomedical Science, 2008
- Calcium Signalling and Disease2007